tert-butyl (2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)carbamate | 194611-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-butyl (2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)carbamate
• 英文别名: (2-Oxo-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester；tert-butyl N-(2-oxo-3,4-dihydro-1H-quinolin-3-yl)carbamate
• CAS: 194611-73-9
• 化学式: C₁₄H₁₈N₂O₃
• 分子量: 262.309
• InChiKey: FKDQTOFAIYTQQY-UHFFFAOYSA-N

物化性质

• 沸点：
  461.2±45.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)carbamate 在 乙酰氯 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 3-amino-1,2,3,4-tetrahydroquinolin-2-one
  参考文献：
  名称：

  Novel 3,4-Dihydroquinolin-2(1 H )-one inhibitors of human glycogen phosphorylase a

  摘要：

  The preparation of a series of substituted indoles coupled to six- and seven-membered cyclic lactams is described and their role as human glycogen phosphorylase a inhibitors discussed. The SAR of the indole moiety and lactam ring are presented. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.022
• 作为产物：
  描述：

  3-amino-1,2,3,4-tetrahydroquinolin-2-one 生成 tert-butyl (2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)carbamate
  参考文献：
  名称：

  Tetrahydroquinoline derivatives as cannabinoid receptor modulators

  摘要：

  该发明提供了式I的化合物，其中取代基如本文所述。进一步提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖、认知障碍、神经系统障碍、疼痛障碍、炎症性障碍、促进戒烟以及治疗其他精神障碍的方法。还提供了含有这些化合物的药物组合物和该发明化合物与其他治疗剂的药物组合。

  公开号：

  US20050009870A1

文献信息

• Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
  申请人：——

  公开号：US20040142938A1

  公开（公告）日：2004-07-22

  Prodrugs of a glycogen phosphorylase inhibiting compounds are provided, said prodrug compounds having the formula I G(—O 2 CR′) m (—OH) n (—O 2 C(CH 2 ) p CH 3 ) q I wherein G is a C 3 to C 5 branched or straight carbon chain and (—O 2 CR′), (—OH) and (—O 2 C(CH 2 ) p CH 3 ) are attached to any available carbon atom along G; m is an integer from 1 to 4; n is an integer from 0 to 3; p is an integer from 0 to 16; q an integer from 0 to 3; where the sum of m, n and q is 3 or 4; and —O 2 CR′ is a fragment of a compound of formula 1 wherein W, X, Y, Z, R 1 and R 2 are as defined herein. Further provided are pharmaceutical compositions and methods for treating diabetes and related diseases employing compounds above, either alone or in combination with another therapeutic agent.

  提供了一种糖原磷酸化酶抑制化合物的前药，所述前药化合物具有以下式I G(—O 2 CR′) m (—OH) n (—O 2 C(CH 2 ) p CH 3 ) q I 其中G是C 3 到C 5 支链或直链碳链，(—O 2 CR′)、(—OH)和(—O 2 C(CH 2 ) p CH 3 )连接到G上的任何可用碳原子上； m是从1到4的整数； n是从0到3的整数； p是从0到16的整数； q是从0到3的整数；其中m、n和q的总和为3或4；以及 —O 2 CR′是具有以下式的化合物的片段 1 其中W、X、Y、Z、R 1 和R 2 如本文所定义。 还提供了使用上述化合物治疗糖尿病和相关疾病的药物组合物和方法，可以单独使用或与另一种治疗剂联合使用。
• Lactam glycogen phosphorylase inhibitors and method of use
  申请人：——

  公开号：US20040002495A1

  公开（公告）日：2004-01-01

  A compound of formula I 1 wherein W is a bicyclic hetroaryl of the structure 2 X is —O—, —S—, —SO 2 —, —CHR 5 —, —CHR 5 O—, —CHR 5 S—, —CHR 5 SO 2 —, —CHR 5 CO— or —CH 2 CHR 5 —; Y is a bond or —CHR 6 —; Z is an aryl or heteroaryl group of the following structure: 3 A is —CH— or —N—; B is —O— or —S—; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as described herein. Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent.

  公式I的化合物 其中 W是具有结构的双环杂芳基 X是—O—，—S—，—SO 2 —，—CHR 5 —，—CHR 5 O—，—CHR 5 S—，—CHR 5 SO 2 —，—CHR 5 CO—或—CH 2 CHR 5 —; Y是一个键或—CHR 6 —; Z是以下结构的芳基或杂芳基团： A是—CH—或—N—; B是—O—或—S—; 和 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 和R 8 如本文所述。 此外，提供了一种治疗糖尿病和相关疾病的方法，该方法使用上述化合物的糖原磷酸化酶抑制剂量，可以单独使用或与另一种治疗剂联合使用。
• S-2-Naphthylmethyl thioacetimidate hydrobromide: A new odorless reagent for the mild synthesis of substituted acetamidines
  作者：Barry G. Shearer、Jeffrey A. Oplinger、Shuliang Lee

  DOI：10.1016/s0040-4039(96)02268-x

  日期：1997.1

  The development, synthesis and use of S-2-naphthylmethyl thioacetimidate hydrobromide 7 as a highly reactive reagent for the mild conversion of amines to substituted acetamidines in a nonodorous process is described.

  描述了S-2-萘甲基硫代乙酰氨基磺酸氢溴酸盐7的开发，合成和用途，它是一种用于在无味过程中将胺轻度转化为取代的乙am的高反应性试剂。
• [EN] 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 1,2,3,4-TÉTRAHYDROQUINOLINE SERVANT D'INHIBITEURS DE L'ACTIVATION DE YAP/TAZ-TEAD POUR LE TRAITEMENT DU CANCER
  申请人：UNIV LEUVEN KATH

  公开号：WO2022072741A1

  公开（公告）日：2022-04-07

  The present invention relates to novel compounds of formula (la), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/ TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/ TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.

  本发明涉及化合物（la）的新颖化合物，以及将该化合物用作药物，更具体地用于预防或治疗由YAP / TAZ-TEAD转录活性介导的疾病，更具体地用于预防或治疗癌症或纤维化。本发明还涉及一种预防或治疗该疾病的方法，包括使用新颖化合物。本发明还涉及新颖化合物的药物组成物或组合制剂，以及将该组成物或制剂用作药物，更具体地用于预防或治疗由YAP / TAZ-TEAD转录活性介导的疾病，更具体地用于预防或治疗癌症或纤维化。本发明还涉及制备该化合物的方法。
• TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Sun Chongqing

  公开号：US20080194625A1

  公开（公告）日：2008-08-14

  The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

  本发明提供了式I的化合物，其中取代基如本文所述。还提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统疾病、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的药物组合物以及本发明化合物与其他治疗剂的药物组合物。